Peter Palese

Affiliations: 
Icahn School of Medicine at Mount Sinai, New York, NY, United States 
Area:
Microbiology Biology
Google:
"Peter Palese"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

González-Domínguez I, Abdeljawad A, Lai TY, et al. (2025) Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models. Frontiers in Immunology. 16: 1524477
Peixoto de Miranda ÉJF, Calado RT, Boulos FC, et al. (2025) Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil. Vaccine. 52: 126680
Slamanig S, Lemus N, Lai TY, et al. (2024) A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge. Vaccine. 45: 126586
González-Domínguez I, Puente-Massaguer E, Abdeljawad A, et al. (2024) Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach. Npj Vaccines. 9: 222
Rathnasinghe R, Chang LA, Pearl R, et al. (2024) Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity. Npj Vaccines. 9: 169
Torres-Flores A, Ontiveros-Padilla LA, Madera-Sandoval RL, et al. (2024) Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals. Frontiers in Immunology. 15: 1394114
Slamanig S, González-Domínguez I, Chang LA, et al. (2024) Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice. Ebiomedicine. 105: 105185
Bliss CM, Nachbagauer R, Mariottini C, et al. (2024) A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein. Ebiomedicine. 104: 105153
Martínez JL, Lemus N, Lai TY, et al. (2024) The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex. Vaccine
Van Reeth K, Parys A, Gracia JCM, et al. (2023) Sequential vaccinations with divergent H1N1 influenza virus strains induce multi-H1 clade neutralizing antibodies in swine. Nature Communications. 14: 7745
See more...